Bharathi Vennapusa

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.2K citations · Full text

Cancer Immunosurveillance, Advanced Lung Disease, Medicine +8

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer et al. · The Lancet Oncology · 2016 · 537 citations · Full text

Dll3-targeted Antibody-drug Conjugate, Medicine, Immunology +6

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Bharathi Vennapusa, Brian M. Baker, Marcin Kowanetz et al. · Applied immunohistochemistry & molecular morphology · 2018 · 185 citations · Full text

Immunology, Immunoediting, Pathology +16

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N

Jacquelyn Smith, Mark D. Robida, Krista Acosta et al. · Diagnostic Pathology · 2016 · 72 citations · Full text

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma

Ahmed O. Kaseb, Manal M. Hassan, Şahin Laçin et al. · Oncotarget · 2016 · 50 citations · Full text

Tumor Biology, Hepatology, Greater Gpc3 Expression +12